🎉 M&A multiples are live!
Check it out!

Werewolf Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Werewolf Therapeutics and similar public comparables like Julphar, Benevolent AI, and Galapagos.

Werewolf Therapeutics Overview

About Werewolf Therapeutics

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.


Founded

2017

HQ

United States of America
Employees

46

Website

werewolftx.com

Financials

LTM Revenue $1.0M

LTM EBITDA n/a

EV

-$39.3M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Werewolf Therapeutics Financials

Werewolf Therapeutics has a last 12-month revenue of $1.0M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Werewolf Therapeutics achieved revenue of $1.9M and an EBITDA of -$64.0M.

Werewolf Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Werewolf Therapeutics valuation multiples based on analyst estimates

Werewolf Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $19.9M $1.9M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$32.5M -$64.0M XXX XXX XXX
EBITDA Margin -163% -3398% XXX XXX XXX
Net Profit -$53.8M -$37.4M XXX XXX XXX
Net Margin -270% -1982% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Werewolf Therapeutics Stock Performance

As of April 15, 2025, Werewolf Therapeutics's stock price is $1.

Werewolf Therapeutics has current market cap of $34.6M, and EV of -$39.3M.

See Werewolf Therapeutics trading valuation data

Werewolf Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$39.3M $34.6M XXX XXX XXX XXX $-1.66

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Werewolf Therapeutics Valuation Multiples

As of April 15, 2025, Werewolf Therapeutics has market cap of $34.6M and EV of -$39.3M.

Werewolf Therapeutics's trades at -38.1x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Werewolf Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Werewolf Therapeutics and 10K+ public comps

Werewolf Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$39.3M XXX XXX XXX
EV/Revenue -20.9x XXX XXX XXX
EV/EBITDA 0.6x XXX XXX XXX
P/E -0.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Werewolf Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Werewolf Therapeutics Valuation Multiples

Werewolf Therapeutics's NTM/LTM revenue growth is -100%

Werewolf Therapeutics's revenue per employee for the last fiscal year averaged $41K, while opex per employee averaged $1.6M for the same period.

Over next 12 months, Werewolf Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Werewolf Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Werewolf Therapeutics and other 10K+ public comps

Werewolf Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -91% XXX XXX XXX XXX
EBITDA Margin -3398% XXX XXX XXX XXX
EBITDA Growth 97% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $41K XXX XXX XXX XXX
Opex per Employee $1.6M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 1010% XXX XXX XXX XXX
R&D Expenses to Revenue 2994% XXX XXX XXX XXX
Opex to Revenue 4004% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Werewolf Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Werewolf Therapeutics M&A and Investment Activity

Werewolf Therapeutics acquired  XXX companies to date.

Last acquisition by Werewolf Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Werewolf Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Werewolf Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Werewolf Therapeutics

When was Werewolf Therapeutics founded? Werewolf Therapeutics was founded in 2017.
Where is Werewolf Therapeutics headquartered? Werewolf Therapeutics is headquartered in United States of America.
How many employees does Werewolf Therapeutics have? As of today, Werewolf Therapeutics has 46 employees.
Who is the CEO of Werewolf Therapeutics? Werewolf Therapeutics's CEO is Dr. Daniel J. Hicklin,, PhD.
Is Werewolf Therapeutics publicy listed? Yes, Werewolf Therapeutics is a public company listed on NAS.
What is the stock symbol of Werewolf Therapeutics? Werewolf Therapeutics trades under HOWL ticker.
When did Werewolf Therapeutics go public? Werewolf Therapeutics went public in 2021.
Who are competitors of Werewolf Therapeutics? Similar companies to Werewolf Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Werewolf Therapeutics? Werewolf Therapeutics's current market cap is $34.6M
What is the current revenue of Werewolf Therapeutics? Werewolf Therapeutics's last 12-month revenue is $1.0M.
What is the current EV/Revenue multiple of Werewolf Therapeutics? Current revenue multiple of Werewolf Therapeutics is -38.1x.
What is the current revenue growth of Werewolf Therapeutics? Werewolf Therapeutics revenue growth between 2023 and 2024 was -91%.
Is Werewolf Therapeutics profitable? Yes, Werewolf Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.